Skip to main content
SpringerLink
Log in

Axitinib plus avelumab or pembrolizumab: management of AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Grunwald V, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer : 26 Jun 2020. Available from: URL: http://doi.org/10.1038/s41416-020-0949-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Axitinib plus avelumab or pembrolizumab: management of AEs. Reactions Weekly 1812, 6 (2020). https://doi.org/10.1007/s40278-020-80485-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-80485-5

Search

Navigation